ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
Novel Treatments, Clinical Research, Medical Community, Entities of Cancer, Diagnosis and Treatment, Difficult to Treat, Updates from Conferences Our MBClife Novel Treatments, Clinical Research, Medical Community, Entities of Cancer, Diagnosis and Treatment, Difficult to Treat, Updates from Conferences Our MBClife

ASCO 2022: When the Dust Settles, Will ADCs Change MBC?

While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.

Read More
Dr. Shanu Modi: How to Get a Standing Ovation at ASCO?
Entities of Cancer, Difficult to Treat, Novel Treatments, Medical Community, Clinical Research, Updates from Conferences Our MBClife Entities of Cancer, Difficult to Treat, Novel Treatments, Medical Community, Clinical Research, Updates from Conferences Our MBClife

Dr. Shanu Modi: How to Get a Standing Ovation at ASCO?

MSK’s Dr. Shanu Modi, lead investigator on the DESTINY-Breast04 trial, talks with the Our MBC Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.

Read More
MBC101: The HER2-Low Show
Essential Knowledge, Entities of Cancer, MBC Imaging and Profiling, Novel Treatments, MBC Patients, Medical Community, Precision Oncology, MBC Stories, Clinical Research, Challenges and Barriers Our MBClife Essential Knowledge, Entities of Cancer, MBC Imaging and Profiling, Novel Treatments, MBC Patients, Medical Community, Precision Oncology, MBC Stories, Clinical Research, Challenges and Barriers Our MBClife

MBC101: The HER2-Low Show

The DESTINY-Breast04 trial at ASCO 2022 introduced many people to the term “HER2-low.” But how do you know if you’re HER2-low? In this episode, with the help a breast pathologist and a clinical oncologist we dive into this subtype and what it means to us.

Read More